Journal of Personalized Medicine最新文献

{"title":"Medium- and Long-Term Evaluation of Splenic Arterial Embolization: A Retrospective CT Volumetric and Hematologic Function Analysis.","authors":"Filippo Piacentino, Federico Fontana, Cecilia Beltramini, Andrea Coppola, Anna Maria Ierardi, Gianpaolo Carrafiello, Giulio Carcano, Massimo Venturini","doi":"10.3390/jpm15090424","DOIUrl":"10.3390/jpm15090424","url":null,"abstract":"<p><p><b>Background:</b> Splenic arterial embolization (SAE) is a well-established technique in the non-operative management of splenic trauma and aneurysms. While its short-term safety and efficacy have been widely documented, medium- and long-term impacts on splenic volume and function remain under-investigated. This study aimed to evaluate volumetric changes and hematological parameters following SAE, with emphasis on its role in preserving splenic integrity and potential integration with AI-enhanced imaging technologies. <b>Methods:</b> We retrospectively analyzed 17 patients treated with SAE between January 2014 and December 2023. Volumetric measurements were performed using computed tomography (CT) with 3D reconstructions before and after SAE. Patients were divided into two groups based on indication: polytrauma (n = 8) and splenic artery aneurysm (n = 9). Hematological parameters including white blood cells (WBCs), red blood cells (RBCs), and hemoglobin (Hb) were evaluated in correlation with clinical outcomes. Statistical significance was assessed using Student's <i>t</i>-test, and power analysis was conducted. <b>Results:</b> Among the trauma group, mean splenic volume decreased from 190.5 ± 51.2 cm³ to 147.8 ± 77.8 cm³ (<i>p</i> = 0.2158), while in the aneurysm group, volume decreased from 195.4 ± 78.9 cm³ to 143.7 ± 81.4 cm³ (<i>p</i> = 0.184). Though not statistically significant, these changes suggest post-procedural splenic remodeling. The technical success of SAE was 100%, with no cases of late follow-up infarction, abscess, immunological impairment, or secondary splenectomy required. Hematologic parameters remained within normal limits in follow-up assessments. <b>Conclusions:</b> SAE represents a safe and effective intervention for spleen preservation in both traumatic and aneurysmal conditions. Although a reduction in splenic volume has been observed, white blood cell counts, a reliable indicator of splenic function, have remained stable over time. This finding supports the preservation of splenic function following SAE.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Prognosis, Risk Assessment, and Management of Patients Diagnosed with Takotsubo Syndrome: A Narrative Review.","authors":"Małgorzata Kosek-Nikołajczuk, Ewa Borowiak, Radoslaw Piatkowski, Marcin Grabowski, Monika Budnik","doi":"10.3390/jpm15090425","DOIUrl":"10.3390/jpm15090425","url":null,"abstract":"<p><p>Takotsubo syndrome (TTS) is a condition marked by sudden and temporary dysfunction of the left ventricle, occurring without significant coronary artery disease. It was previously thought to be a benign and self-limiting condition, associated with a favorable long-term prognosis and minimal impact on survival. However, the most recent findings provide evidence that TTS is a heterogeneous condition with various presentation patterns. Using the most recent evidence regarding long-term prognosis in TTS, this review article aims to provide an overview of the long-term survival of patients with TTS, highlighting potential risk factors and comorbidities that may worsen prognosis. It also explores the risk of recurrence and the utility of advanced imaging modalities for prognosis assessment. Risk factors negatively impacting long-term outcomes include male sex, older age, reduced left ventricular ejection fraction (LVEF), physical triggers (especially pulmonary and neurological diseases), and comorbidities such as atrial fibrillation, chronic obstructive pulmonary disease, and active cancer. Recurrence, though relatively uncommon, can affect up to 11% of patients, with \"super recurrence\" linked to higher peak troponin levels, lower LVEF, and emotional triggers. Advanced imaging modalities-such as coronary angiography and ventriculography, which are considered the gold standard, along with serial echocardiographic assessment-combined with cardiac biomarkers, including relatively low peak troponin levels and markedly elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), as well as diagnostic ratios like copeptin/NT-proBNP, provide a robust framework for differentiating TTS from acute coronary syndromes. Key findings suggest that chronic therapeutic strategies in the long-term management of TTS patients should focus on improving long-term outcomes and reducing the risk of mortality and TTS recurrence. Methods: A comprehensive review was conducted using PubMed (U.S. National Library of Medicine and National Institutes of Health) and Google Scholar to identify relevant English-language publications addressing the long-term prognosis, biomarkers, imaging, risk of recurrence, and long-term management of TTS.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The State of the Art in the Treatment of Actinic Keratosis and Field Cancerization: A Narrative Review.","authors":"Andrea Paradisi, Enrico Bocchino, Maria Mannino, Giulio Gualdi, Alessandra D'Amore, Daniele Omar Traini, Ketty Peris","doi":"10.3390/jpm15090421","DOIUrl":"10.3390/jpm15090421","url":null,"abstract":"<p><p>Actinic keratosis (AK) is considered the early phase of a squamous cell carcinoma (SCC) and represents one of the most common epithelial skin lesions, with an estimated global prevalence of approximately 14%. An estimated annual risk of progression has been reported with a range from 0 to 0.53%. Although spontaneous regression of individual AK lesions has been described in approximately 23% of cases, the frequent presence of multiple lesions, usually in the broader context of field cancerization, significantly diminishes the likelihood of regression and contributes to a higher cumulative risk of progression to SCC. The aim of the present narrative review was to provide an overview of the current evidence of the most effective available lesion-directed and field-directed treatments for actinic keratoses, on the personalized, combined, or sequential approach, as well as on the emerging therapeutic options.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium Hides the Clue: Unraveling the Diagnostic Value of Coronary Calcium Scoring in Cardiac Arrest Survivors.","authors":"Ana Margarida Martins, Joana Rigueira, Beatriz Valente Silva, Beatriz Nogueira Garcia, Pedro Alves da Silva, Ana Abrantes, Rui Plácido, Doroteia Silva, Fausto J Pinto, Ana G Almeida","doi":"10.3390/jpm15090422","DOIUrl":"10.3390/jpm15090422","url":null,"abstract":"<p><p><b>Introduction</b>: Coronary artery disease remains one of the most prevalent causes of hospital cardiac arrest (OHCA). Although the benefit of early coronary angiography is well stablished in patients with ST-segment elevation, the benefit and the timing of performing it in other patients remain a matter of debate. This is due to the difficulty of identifying those in which an infarction with non-ST-segment elevation is the cause of the OHCA. Coronary artery calcium (CAC) emerges as a reliable predictor of coronary disease and adverse cardiovascular events, detectable even in non-gated chest computed tomography (CT) scans commonly used in OHCA etiological studies, showcasing potential for streamlined risk assessment and management. <b>Aim</b>: The aim of this study was to evaluate if CAC in non-gated CT scans performed in OHCA survivors could act as a good predictor of coronary artery disease on coronary angiography. <b>Methods</b>: This is a single-center, retrospective study of OHCA survivors without ST-segment elevation at presentation. We selected patients for whom a non-gated chest CT was performed and underwent coronary angiography due to the clinical, electrocardiogram (ECG), or echocardiographic suspicion of acute coronary syndrome. An investigator, blinded to the coronary angiography report, evaluated CAC both quantitively (with Agatston score) and qualitatively (visual assessment: absent, mild, moderate, or severe). <b>Results</b>: A total of 44 consecutive patients were included: 70% male, mean age of 60 ± 13 years old. The mean Agatston score was 396 ± 573 AU (Agatston units). Regarding the qualitative assessment, CAC was classified as mild, moderate, and severe in 11%, 25%, and 20% of patients, respectively. The coronary angiography revealed significant coronary lesions in 15 patients (34%), of which 87% were revascularized (80% underwent PCI and 7% CABG). The quantitative CAC assessment accurately predicted the presence of significant lesions on coronary angiography (AUC = 0.90, 95% CI 0.81-0.99, <i>p</i> < 0.001). The presence of moderate or severe CAC by visual assessment also predicted significant lesions on coronary angiography (OR 2.66, 95% CI 1.87-109.71, <i>p</i> = 0.01). There was also a good and significant correlation between the vessel with severe calcification in the CT scan and the culprit vessel evaluated by coronary angiography. CAC was reported in only 16% of the reviewed CTs, most of them with severe calcification. <b>Conclusion</b>: The assessment of CAC in non-gated chest CT scans proved to be feasible and displayed a robust correlation with the presence, severity, and location of coronary artery disease. Its routine use upfront was shown to be an important complement to CT scan reports, ensuring more precise and personalized OHCA management.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Splenic Artery Embolization in Blunt Splenic Trauma: Insights from an Italian Multicenter Cohort.","authors":"Fabio Corvino, Francesco Giurazza, Marcello Andrea Tipaldi, Tommaso Rossi, Francesco Daviddi, Orsola Perrone, Ilaria Ambrosini, Mauro D'addato, Ilaria Villanova, Paolo Marra, Francesco Saverio Carbone, Antonio Vizzuso, Fernando Smaldone, Anna Rita Scrofani, Roberto Iezzi, Andrea Discalzi, Marco Calandri, Marco Femia, Carlo Valenti Pittino, Ruggero Vercelli, Daniele Falsaperla, Antonello Basile, Antonio Bruno, Chiara Gasperini, Raffaella Niola","doi":"10.3390/jpm15090420","DOIUrl":"10.3390/jpm15090420","url":null,"abstract":"<p><p><b>Background:</b> Splenic artery embolization (SAE) has emerged as a key adjunct to non-operative management (NOM) in hemodynamically stable patients with blunt splenic trauma, yet variability in its application persists across centers. <b>Objectives:</b> The aim was to evaluate real-life clinical practices, techniques, and outcomes of SAE in blunt splenic trauma across multiple Italian trauma centers. <b>Materials and Methods:</b> This retrospective multicenter study analyzed data from 281 patients undergoing emergency SAE for blunt splenic trauma between January 2019 and December 2021. Demographics, imaging findings, embolization techniques, complications, and outcomes were collected and analyzed. Multivariate logistic regression was used to assess predictors of splenectomy. <b>Results:</b> The technical success rate was 100%, with a 9.6% rate of post-embolization splenectomy and a complication rate of 24.9% (including 5.7% splenic infarction and 3.2% rebleeding). Embolization was performed proximally (46.6%), distally (28.8%), or with a combined approach (24.6%). No significant correlation was found between embolization technique and splenectomy rate. Patients with AAST grade III injuries benefited from SAE with high technical success and low failure rates. Notably, 14.2% of patients underwent angiography despite negative CT, with a splenectomy rate of 10% in this subgroup. Multivariate analysis identified no independent predictors of splenectomy. <b>Conclusions:</b> SAE is a reliable and effective tool in the management of blunt splenic trauma, achieving high splenic salvage rates even in selected grade III injuries and CT-negative patients. In an era of precision medicine, interventional radiology should be regarded as a distinct and specific treatment modality, comparable to surgery, rather than being merely included within non-operative management (NOM).</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transoral Robotic Surgery for the Salvage of Primarily Irradiated Oropharyngeal Squamous Cell Carcinomas Recurring at the Base of the Tongue: A Small Monoinstitutional Series.","authors":"Samuele Frasconi, Davide Rizzo, Roberto Gallus, Nikolaos Machouchas, Sergio Cannova, Dan Marian Fliss, Jacopo Galli, Francesco Bussu","doi":"10.3390/jpm15090419","DOIUrl":"10.3390/jpm15090419","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Recurrences of squamous cell carcinoma (SCC) at the base of the tongue (BoT) after primary radiochemotherapy (RT-CHT) are associated with low survival rates, poor functional outcomes, and high morbidity following salvage surgery. Transoral robotic surgery (TORS) has emerged as a less invasive alternative to open surgical approaches. This study aims to describe our clinical experience with TORS in patients with BoT SCC recurrence after RT-CHT, focusing on oncological outcomes-relapse-free survival (RFS) and disease-specific survival (DSS)-as well as functional outcomes, particularly swallowing function. <b>Methods</b>: We conducted a retrospective review of four patients who underwent salvage TORS for BoT recurrence between September 2013 and September 2014 at a single tertiary referral center. All patients had been previously treated with primary RT-CHT for oropharyngeal squamous cell carcinomas. Oncological events (recurrence, death) and functional endpoints (dietary limitations, MD Anderson Dysphagia Inventory [MDADI] scores) were retrieved from medical records. <b>Results</b>: Four patients were included. All achieved unrestricted oral intake by one month post-TORS, showing functional improvement compared to their preoperative status. Three of the four patients remained free of locoregional recurrence during follow-up. No major perioperative complications were reported. <b>Conclusions</b>: In selected patients with BoT SCC recurrence after primary RT-CHT, TORS may offer a viable and less morbid salvage treatment option with favorable early functional outcomes and acceptable oncologic control. Based on both our institutional experience and the supporting literature, we propose selection criteria to guide TORS indication in this clinical setting.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Piloting of Co.Ge.: A Web-Based Digital Platform for Generative and Clinical Cognitive Assessment.","authors":"Angela Muscettola, Martino Belvederi Murri, Michele Specchia, Giovanni Antonio De Bellis, Chiara Montemitro, Federica Sancassiani, Alessandra Perra, Barbara Zaccagnino, Anna Francesca Olivetti, Guido Sciavicco, Rosangela Caruso, Luigi Grassi, Maria Giulia Nanni","doi":"10.3390/jpm15090423","DOIUrl":"10.3390/jpm15090423","url":null,"abstract":"<p><p><b>Background/Objectives</b>: This study presents Co.Ge. a Cognitive Generative digital platform for cognitive testing. We describe its architecture and report a pilot study. <b>Methods</b>: Co.Ge. is modular and web-based (Laravel-PHP, MySQL). It can be used to administer a variety of validated cognitive tests, facilitating administration and scoring while capturing Reaction Times (RTs), trial-level responses, audio, and other data. Co.Ge. includes a study-management dashboard, Application Programming Interfaces (APIs) for external integration, encryption, and customizable options. In this demonstrative pilot study, clinical and non-clinical participants completed an Auditory Verbal Learning Test (AVLT), which we analyzed using accuracy, number of recalled words, and reaction times as outcomes. We collected ratings of user experience with a standardized rating scale. Analyses included Frequentist and Bayesian Generalized Linear Mixed Models (GLMMs). <b>Results</b>: Mean ratings of user experience were all above 4/5, indicating high acceptability (<i>n</i> = 30). Pilot data from AVLT (<i>n</i> = 123, 60% clinical, 40% healthy) showed that Co.Ge. seamlessly provides standardized clinical ratings, accuracy, and RTs. Analyzing RTs with Bayesian GLMMs and Gamma distribution provided the best fit to data (Leave-One-Out Cross-Validation) and allowed to detect additional associations (e.g., education) otherwise unrecognized using simpler analyses. <b>Conclusions</b>: The prototype of Co.Ge. is technically robust and clinically precise, enabling the extraction of high-resolution behavioral data. Co.Ge. provides traditional clinical-oriented cognitive outcomes but also promotes complex generative models to explore individualized mechanisms of cognition. Thus, it will promote personalized profiling and digital phenotyping for precision psychiatry and rehabilitation.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Complications Are Increased in Inflammatory Bowel Disease: A Path Toward Achievement of a Personalized Risk Estimation.","authors":"Vito Annese, Maria Laura Annunziata, Guglielmo Albertini Petroni, Emanuele Orlando, Sofia Cinque, Marzio Parisi, Paolo Biamonte, Giuseppe Dell'Anna, Anna Latiano, Serenella Castelvecchio","doi":"10.3390/jpm15090418","DOIUrl":"10.3390/jpm15090418","url":null,"abstract":"<p><p><b>Background/Objectives</b>: The global burden of inflammatory bowel diseases (IBDs) continues to rise, with up to 50% of patients experiencing extraintestinal manifestations. Cardiovascular diseases (CVDs) are of particular concern, ranking as the second leading cause of mortality in this population. Despite a comparatively lower prevalence of traditional cardiovascular (CV) risk factors, the persistent inflammatory milieu and immune dysregulation inherent to IBD may contribute to heightened CVD risk. In this study, following a review of the current literature, an ongoing prospective trial designed to clarify CV risk profiles in IBD patients is detailed. <b>Methods</b>: A cohort of patients with IBD is being enrolled for comprehensive baseline evaluation of CV risk factors, lifestyle metrics, and disease characteristics. The incidence of major adverse cardiovascular events (MACEs) will be tracked and contrasted with a gender- and age-matched non-IBD cohort over a 2-year follow-up period. In cases of MACE occurrence, a multi-omics analysis-including genomic, proteomic, transcriptomic, and microbiome profiling-will be performed, along with a parallel evaluation in matched IBD controls without MACE. An artificial intelligence (AI) framework will support the analysis of this complex dataset. <b>Results</b>: To date, over 150 patients with IBD have been enrolled, and detailed phenotypic data and biological samples have been collected. <b>Conclusions</b>: We aim to introduce an IBD-specific correction factor for existing CV risk scores upon study completion. This is particularly relevant for individuals under 40 years of age, who are often inadequately assessed by current risk stratification models.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study.","authors":"Sunjin Hwang, Rim Kyung Hong, Eun Hee Hong, Min Ho Kang, Yong Un Shin","doi":"10.3390/jpm15090409","DOIUrl":"10.3390/jpm15090409","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Chronic central serous chorioretinopathy (cCSC) is a vision-threatening disorder characterized by persistent subretinal fluid (SRF). While several treatment options exist, their efficacy varies, and optimal management remains uncertain. This retrospective pilot study aimed to evaluate the efficacy and safety of intravitreal brolucizumab in patients with symptomatic cCSC without pachychoroid neovasculopathy (PNV). <b>Methods:</b> In total, 15 eyes of 15 patients diagnosed with symptomatic cCSC without PNV were treated with a single intravitreal injection of brolucizumab. Patients were followed for six months. Primary outcomes included resolution of SRF and changes in central subfield thickness (CST) and subfoveal choroidal thickness (SCT). Best-corrected visual acuity (BCVA) and ocular safety profiles were also assessed. <b>Results:</b> Complete SRF resolution was observed in 14 of 15 eyes (93.3%) within six months. Mean CST significantly decreased from 317.13 ± 73.40 µm to 205.53 ± 20.17 µm (<i>p</i> < 0.001), and mean SCT from 475.87 ± 107.66 µm to 390.13 ± 121.67 µm (<i>p</i> < 0.001). BCVA improved in 12 eyes (80.0%) and remained stable in 3 eyes; however, the mean improvement (logMAR 0.34 ± 0.33 to 0.14 ± 0.13) was statistically significant (<i>p</i> = 0.007). No significant ocular adverse events were reported. <b>Conclusions:</b> Intravitreal brolucizumab may be an effective and safe treatment for reducing SRF and choroidal thickness in patients with cCSC without PNV. Larger, controlled studies are needed to validate these findings.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging Epilepsy and Cognitive Impairment: Insights from EEG and Clinical Observations in a Retrospective Case Series.","authors":"Athanasios-Christos Kalyvas, Nikoletta Smyrni, Panagiotis Ioannidis, Nikolaos Grigoriadis, Theodora Afrantou","doi":"10.3390/jpm15090413","DOIUrl":"10.3390/jpm15090413","url":null,"abstract":"<p><p><b>Background</b>: Epilepsy and cognitive impairment frequently coexist, yet their relationship remains complex and insufficiently understood. This study aims to explore the clinical and electrophysiological features of patients presenting with both conditions in order to identify patterns that may inform more accurate diagnosis and effective management within a personalized medicine framework. <b>Methods</b>: We retrospectively analyzed 14 patients with late-onset epilepsy and coexisting cognitive impairment, including mild cognitive impairment and Alzheimer's disease. Clinical history, cognitive assessments, neuroimaging, and electroencephalographic recordings were reviewed. EEG abnormalities, seizure types, and treatment responses were systematically documented. <b>Results</b>: Patients were categorized into two groups: (1) those with established Alzheimer's disease who later developed epilepsy and (2) those in whom epilepsy preceded cognitive impairment. Temporal lobe involvement was a key feature, with EEG abnormalities frequently localizing to the frontal-temporal electrodes and manifesting as background slowing, focal multiform slow waves, and epileptiform discharges. Levetiracetam was the most commonly used antiseizure medication, and it was effective across both groups. <b>Conclusions</b>: This case series highlights the value of EEG in characterizing patients with subclinical and overt epileptic activity and cognitive impairment comorbidity. The inclusion of a substantial number of cases with documented EEG abnormalities provides valuable insight into the interplay between epilepsy and neurodegenerative diseases. By integrating neurophysiological data with clinical and cognitive trajectories, this work aligns with the principles of precision medicine, facilitating a more comprehensive evaluation and tailored management approach. Further longitudinal studies are required to validate prognostic markers and guide optimal therapeutic strategies.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}